ArriVent BioPharma, Inc. Common Stock
AVBPArriVent BioPharma, Inc.
NASDAQ
Healthcare
Biotechnology
$24.68
+0.46(1.90%)
52W $16.30 – $26.56
AI-generated
ArriVent BioPharma, Inc.
$1.1BMkt Cap
—Rev TTM
-$191MNI TTM
-5.1xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 4, 2026ArriVent BioPharma, Inc. (AVBP), a clinical-stage biopharmaceutical company, reported a net loss of $166.3 million for FY 2025, up 106.6% from $80.5 million in FY 2024, driven by intensified R&D investments in its lead candidate firmonertinib and early-stage programs. Total operating expenses surged to $177.5 million from $94.3 million YoY, with R&D expenses comprising $153.4 million (up 94.1%) due to...
Fundamentals
How The Business Makes Money
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Industry Biotechnology
Analyst View
Company Profile
CIK0001868279
ISINUS04272N1028
CUSIP04272N102
Phone628-277-4836
Address18 Campus Boulevard, Newtown Square, 19073, US
SEC EDGAR